Alex Borchert1, David A Leavitt2. 1. Vattikuti Urology Institute, Henry Ford Hospital, Henry Ford Health System, 2799 West Grand Boulevard, K9, Detroit, MI, 48202, USA. 2. Vattikuti Urology Institute, Henry Ford Hospital, Henry Ford Health System, 2799 West Grand Boulevard, K9, Detroit, MI, 48202, USA. dleavit1@hfhs.org.
Abstract
PURPOSE OF REVIEW: Review how the various surgical treatments for benign prostatic hyperplasia and lower urinary tract symptoms impact on male sexual health and function. RECENT FINDINGS: The interplay between benign prostatic hyperplasia and erectile function is complex, and the conditions seem linked. Most cavitating procedures to improve male voiding will degrade ejaculatory and possibly erectile function. Many of the newer minimally invasive therapies appear to preserve sexual function in the short term while sacrificing some of the voiding improvements realized with more complete removal of the prostate adenoma. Benign prostatic hyperplasia will affect the majority of men at some point in life, and surgical treatment remains an integral option for managing the associated urinary symptoms. These treatments are associated with variable rates of sexual side effects, including ejaculatory, erectile, and orgasmic dysfunction. As the impact of these treatment modalities on sexual dysfunction has become more widely acknowledged, there has been a rise in interest in modalities that minimize adverse sexual side effects. Recent studies have sought to further elucidate the relationship between surgical treatment of benign prostate hyperplasia and sexual outcomes, and a number of studies have demonstrated that treatment of benign prostate hyperplasia can actually result in improved sexual function for some patients. This work intends to review the proposed pathophysiology behind the sexual side effects resulting from the surgical treatment of benign prostate hyperplasia and review the literature regarding both established and emerging surgical techniques.
PURPOSE OF REVIEW: Review how the various surgical treatments for benign prostatic hyperplasia and lower urinary tract symptoms impact on male sexual health and function. RECENT FINDINGS: The interplay between benign prostatic hyperplasia and erectile function is complex, and the conditions seem linked. Most cavitating procedures to improve male voiding will degrade ejaculatory and possibly erectile function. Many of the newer minimally invasive therapies appear to preserve sexual function in the short term while sacrificing some of the voiding improvements realized with more complete removal of the prostate adenoma. Benign prostatic hyperplasia will affect the majority of men at some point in life, and surgical treatment remains an integral option for managing the associated urinary symptoms. These treatments are associated with variable rates of sexual side effects, including ejaculatory, erectile, and orgasmic dysfunction. As the impact of these treatment modalities on sexual dysfunction has become more widely acknowledged, there has been a rise in interest in modalities that minimize adverse sexual side effects. Recent studies have sought to further elucidate the relationship between surgical treatment of benign prostate hyperplasia and sexual outcomes, and a number of studies have demonstrated that treatment of benign prostate hyperplasia can actually result in improved sexual function for some patients. This work intends to review the proposed pathophysiology behind the sexual side effects resulting from the surgical treatment of benign prostate hyperplasia and review the literature regarding both established and emerging surgical techniques.
Entities:
Keywords:
BPH; Benign prostatic hyperplasia; Erectile dysfunction; LUTS; Lower urinary tract symptoms; Sexual function
Authors: Ryan W Frieben; Hao-Cheng Lin; Peter P Hinh; Francesco Berardinelli; Steven E Canfield; Run Wang Journal: Asian J Androl Date: 2010-05-17 Impact factor: 3.285
Authors: Peter J Gilling; Liam C Wilson; Colleen J King; Andre M Westenberg; Christopher M Frampton; Mark R Fraundorfer Journal: BJU Int Date: 2011-08-23 Impact factor: 5.588
Authors: Peter Gilling; Neil Barber; Mohamed Bidair; Paul Anderson; Mark Sutton; Tev Aho; Eugene Kramolowsky; Andrew Thomas; Barrett Cowan; Ronald P Kaufman; Andrew Trainer; Andrew Arther; Gopal Badlani; Mark Plante; Mihir Desai; Leo Doumanian; Alexis E Te; Mark DeGuenther; Claus Roehrborn Journal: J Urol Date: 2018-01-31 Impact factor: 7.450
Authors: José Placer; Carlos Salvador; Jacques Planas; Enrique Trilla; David Lorente; Ana Celma; Miguel Ángel López; Juan Morote Journal: J Endourol Date: 2014-10-21 Impact factor: 2.942
Authors: P Capogrosso; E Ventimiglia; M Ferrari; A Serino; L Boeri; U Capitanio; A Briganti; R Damiano; F Montorsi; A Salonia Journal: Int J Impot Res Date: 2016-07-28 Impact factor: 2.896
Authors: Moritz F Hamann; Carsten M Naumann; Christof Seif; Christof van der Horst; Klaus-Peter Jünemann; Peter M Braun Journal: Eur Urol Date: 2008-05-16 Impact factor: 20.096
Authors: Marta Tenuta; Maria G Tarsitano; Paola Mazzotta; Livia Lucchini; Franz Sesti; Giorgio Fattorini; Carlotta Pozza; Valerio Olivieri; Fabio Naro; Daniele Gianfrilli; Andrea Lenzi; Andrea M Isidori; Riccardo Pofi Journal: Andrology Date: 2020-03-16 Impact factor: 3.842